GSK exercises global licence option for Adaptimmune ’s NY-ESO-1 T-cell therapy

GlaxoSmithKline (GSK) has exercised the option to obtain an exclusive global licence from Adaptimmune Therapeutics for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals